GlassScriptPhysician profile
Matthew P Harrison
NPI 1003263419
$7,024.36
in general payments reported to CMS, 2019-2025
29 companies · $2,083 in 2025
The $2,083 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.78 · 2020: $1,667 · 2021: $554 · 2022: $514 · 2023: $915 · 2024: $1,261 · 2025: $2,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,222 · Education: $36.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,222.47 |
| Education | $36.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $1,666.67 | 2020 | |
| Abbvie INC. | $1,393.42 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $601.84 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $433.09 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $391.34 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $358.15 | 2021-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $302.72 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $241.98 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $206.91 | 2024-2025 | Voquezna |
| Medtronic, INC. | $164.35 | 2021-2022 | |
| Celgene Corporation | $163.49 | 2022-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $124.90 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $111.64 | 2022-2025 | Dupixent |
| Genzyme Corporation | $108.41 | 2023-2024 | |
| Celltrion USA INC. | $107.36 | 2024-2025 | Vegzelma, Zymfentra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $100.63 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $99.64 | 2021 | |
| Braintree Laboratories, INC. | $90.78 | 2024-2025 | Sutab, Suflave |
| Boston Scientific Corporation | $84.93 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $69.27 | 2023-2024 | Ocaliva |
| Merck Sharp & Dohme LLC | $57.33 | 2023-2024 | Dificid |
| Qol Medical, LLC | $26.68 | 2025 | Sucraid |
| Ferring Pharmaceuticals INC. | $24.47 | 2023 | Rebyota |
| Amgen INC. | $18.57 | 2023 | Amjevita, Avsola |
| Aimmune Therapeutics, INC. | $18.52 | 2025 | Zenpep |
| Azurity Pharmaceuticals, INC. | $15.35 | 2025 | Suflave |
| Biocon Biologics INC | $15.12 | 2025 | Yesintek |
| Micro-Tech Endoscopy USA, INC. | $14.74 | 2025 | Riteclip |
| Redhill Biopharma INC. | $12.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.